Hologic stock holds near 52-week high as recent earnings support valuation

Published on 09/11/2026 at 14:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hologic stock trades close to its 52-week high as of September 10, 2026, supported by solid recent earnings and a consensus Hold rating. The shares’ upside looks limited with an average analyst price target only modestly above the current level.

Hologic, US4364401012, Illustration mit AI erstellt.

Hologic, Inc. stock (ISIN US4364401012) is trading close to its 52-week high as of September 10, 2026, with a recent market capitalization of about USD 16.97 billion highlighting investors’ confidence in the medical technology group’s earnings power.

Stock near top of recent trading range

According to MarketBeat on September 10, 2026, Hologic stock trades on Nasdaq under the ticker HOLX, with a 52-week range from USD 51.90 to USD 76.07, placing the current price band very close to the upper end of that corridor.

The same overview shows a recent market capitalization of USD 16.97 billion and a price-to-earnings ratio of 31.67, indicating that the shares are valued at more than thirty times trailing earnings, a level that reflects the market’s expectation for continued cash generation and growth from the company.

Recent earnings underpin valuation

Hologic reported its last earnings on January 29, 2026 for its fiscal year running to September 30, 2026, with the figures representing the most recent results available to investors and forming the basis for the current valuation on Nasdaq, as noted by MarketBeat.

In addition, Hologic appears among leading healthcare names by return on assets in a 2026 ranking, where the company is listed with a ROA of 6.28 percent alongside a market capitalization of USD 16.97 billion, according to StockTitan. This level of asset profitability gives investors a concrete benchmark for comparing Hologic to other healthcare equipment and supplies companies.

Analyst view: consensus Hold with limited upside

The analyst community currently takes a cautious stance on Hologic stock. According to MarketBeat on September 10, 2026, the shares carry a consensus rating of Hold based on 12 Hold recommendations and no Buy or Strong Buy ratings, with an average price target of USD 79.13.

With the consensus price target of USD 79.13 only modestly above the recent price level and the 52-week high of USD 76.07, the implied potential upside of around 4.1 percent suggests that many analysts see Hologic stock as fairly valued in the short term rather than a clear bargain or a high-risk name at current levels, according to the same MarketBeat data.

Price context for investors

On Nasdaq, Hologic stock recently traded in a daily range between USD 76.00 and USD 76.07, close to its identified 52-week high of USD 76.07, while the lower end of the 52-week corridor stands at USD 51.90, per the September 10, 2026 overview from MarketBeat. For investors, this positioning near the top of the year’s band is a clear signal that the market currently prices Hologic as a relatively robust healthcare equipment name.